TLR9 and neoplasm: Conjugation of STAT3ASO to CpG oligonucleotide, a TLR9 agonist, facilitates targeting of TLR9-expressing immune cells, such as human and mouse tumor-associated MDSCs (25) and macrophages (26), plasmacytoid DCs, and B cells but not T cells (27).